Matrix metalloproteinases (MMP) 3 and 9 as biomarkers of severity in COVID-19 patients.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
24 01 2022
24 01 2022
Historique:
received:
23
06
2021
accepted:
15
11
2021
entrez:
25
1
2022
pubmed:
26
1
2022
medline:
3
2
2022
Statut:
epublish
Résumé
The molecular basis of the wide clinical heterogeneity of Coronavirus disease 2019 (COVID-19) is still unknown. Matrix metalloproteinases (MMPs) may have a role in the lung damage and regeneration that occur in severe patients. We studied serum MMP3 and MMP9 as potential biomarkers of COVID-19 severity, in 108 hospitalized patients with different World Health Organization (WHO) severity stage and in 48 controls. At hospital admission, serum MMP3 was increased in COVID-19 patients with a significant trend along the progression of the WHO stage, while serum levels of MMP9 were significantly increased in COVID-19 patients with no correlation with disease severity. At 1 week from hospitalization, MMP3 was reduced, suggesting an early pathogenic role of the protein in lung inflammation, while MMP9 levels were further increased, indicating a late role of the protein in the inflammatory process, specifically during the repairing phase. Furthermore, serum MMP9 was positively correlated with serum interleukin-6, myeloperoxidase, and circulating neutrophils and monocytes number. In conclusion, serum MMP3 may help to early predict the severity of COVID-19 and both proteins, MMP3 and MMP9, may contribute to define severe COVID-19 patients that may benefit from a targeted therapy on MMPs.
Identifiants
pubmed: 35075175
doi: 10.1038/s41598-021-04677-8
pii: 10.1038/s41598-021-04677-8
pmc: PMC8786927
doi:
Substances chimiques
Biomarkers
0
MMP3 protein, human
EC 3.4.24.17
Matrix Metalloproteinase 3
EC 3.4.24.17
MMP9 protein, human
EC 3.4.24.35
Matrix Metalloproteinase 9
EC 3.4.24.35
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1212Subventions
Organisme : Regione Campania
ID : CEINGE-TASK-force COVID-19, code D64I200003800
Informations de copyright
© 2022. The Author(s).
Références
J Infect. 2020 Sep;81(3):e41-e43
pubmed: 32603675
Life Sci. 2020 Sep 15;257:118096
pubmed: 32679150
N Engl J Med. 2020 Oct 29;383(18):1757-1766
pubmed: 32329974
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990
Life Sci. 2020 Nov 15;261:118355
pubmed: 32871183
Int J Mol Sci. 2020 Nov 20;21(22):
pubmed: 33233715
Exp Mol Pathol. 2007 Oct;83(2):169-76
pubmed: 17540368
Exp Mol Pathol. 2004 Jun;76(3):189-95
pubmed: 15126100
Am J Respir Cell Mol Biol. 2003 Jan;28(1):12-24
pubmed: 12495928
Shock. 2015 Aug;44(2):128-36
pubmed: 26009816
Eur Respir J. 2011 Oct;38(4):959-70
pubmed: 21565917
Med Drug Discov. 2020 Sep;7:100052
pubmed: 32537610
JCI Insight. 2021 Jan 11;6(1):
pubmed: 33232303
Infect Disord Drug Targets. 2021;21(6):e170721187996
pubmed: 33200717
J Med Virol. 2021 Jan;93(1):528-532
pubmed: 32603484
N Engl J Med. 2020 Dec 17;383(25):2451-2460
pubmed: 32412710
Biochim Biophys Acta. 2014 Aug;1840(8):2571-80
pubmed: 24631662
Front Public Health. 2021 Jun 15;9:664108
pubmed: 34211953
Expert Rev Respir Med. 2014 Aug;8(4):411-21
pubmed: 24869454
Diagnostics (Basel). 2021 Feb 12;11(2):
pubmed: 33673182